Do proton pump inhibitors increase the risk of dementia? A systematic review, meta‐analysis and bias analysis. Issue 2 (23rd November 2022)

• Record Type: Journal Article
• Authors: Ahn, Nayeon; Nolde, Michael; Krause, Evamaria; Güntner, Florian; Günter, Alexander; Tauscher, Martin; Gerlach, Roman; Meisinger, Christa; Linseisen, Jakob; Baumeister, Sebastian‐Edgar; Rückert‐Eheberg, Ina‐Maria
• Other Names: Rieder Michael guestEditor.; Likic Robert guestEditor.
• Is Part Of: British journal of clinical pharmacology. Volume 89:Issue 2(2023)
• Page Start: 602
• Page End: 616
• Publication Date: 2022-11-23
• Subjects: Alzheimer's disease -- cognitive impairment -- dementia -- proton pump inhibitors; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.15583
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aim: Previous studies on the association between proton pump inhibitor (PPI) intake and the increased risk of dementia has shown discrepancies in their conclusions. We aimed to provide updated evidence based on extensive bias assessments and quantitative sensitivity analyses. Methods: We searched the databases PubMed, EMBASE, SCOPUS, CENTRAL and clinicaltrials.gov for prospective studies that examined an association between PPI use and dementia, up to February 2022. Each study was assessed using the Cochrane risk of bias assessment tools for non‐randomized studies of interventions (ROBINS‐I) or randomized trials (RoB2). Pooled risk ratios (RRs) and 95% prediction intervals were computed using random‐effects models. Sensitivity analyses were adjusted for small‐study bias. Results: We included nine observational studies with 204 108 dementia cases in the primary analysis on the association between PPI use vs . non‐use and dementia, and the RR was 1.16 (95% CI = 1.00; 1.35). After adjusting for small‐study bias by Copas selection model and Rücker's shrinkage procedure, the RR was 1.16 (1.02; 1.32) and 1.15 (1.13; 1.17), respectively. A subgroup analysis of PPI use vs . non‐use regarding Alzheimer's disease risk yielded an RR of 1.15 (0.89; 1.50). The secondary analysis on the risk of dementia by use of PPI vs . histamine‐2 receptor antagonist showed an RR of 1.03 (0.66; 1.62). Conclusion: This meta‐analysis provided no clear evidence for an association between PPI intake and the risk of dementia. Due to discrepancies in sensitivity analyses, however, some risk of dementia by PPI use cannot be ruled out. Since an unequivocal conclusion is still pending, further research is warranted.